Efficacy of MMR vaccine in warts

Efficacy of intralesional Measles Mumps Rubella Vaccine in treatment of Verruca Vulgaris-An interventional study

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2018/10/016238

Enrollment

100

Registered

2018-10-31

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L088- Other specified local infections of the skin and subcutaneous tissue

Interventions

Intervention1: Intralesional MMR vaccine: 0.3 ml intralesional MMR vaccine to be given in base of largest wart Control Intervention1: Cryotherapy: Crotherapy done every 2 weeks on each wart

Eligibility

Inclusion criteria

Inclusion criteria: cases with multiple Common warts(more than 5 warts at single anatomical site or 1 or more warts at more than 2 anatomical sites who did recieve any treatment for warts in last 2 weeks

Exclusion criteria

Exclusion criteria: 1 Cases with verruca plana or anogenital warts 2 Females of child bearing potential 3 Cases with systemic or other cutaneous disease 4 Immunocompromised cases

Design outcomes

Primary

Measure	Time frame
Efficacy of VaccineTimepoint: At 3 weeks, 6 weeks and 9 weeks	—

Secondary

Measure	Time frame
Adverse reactionTimepoint: 7 months	—

Countries

India

Contacts

Public ContactAshma Surani

Medical college Vadodara

ym11256@gmail.com9825917442

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026